title: Unexpectedly high prevalence of pretransplant abnormal glucose tolerance in pediatric kidney transplant recipients.
abstract: Several studies suggested that the incidence of new-onset diabetes following pediatric kidney transplantation has increased markedly in recent years, with reported incidence of up to 20%. However, limited information is available regarding the incidence and features of pretransplant status of abnormal glucose tolerance in pediatric kidney transplant recipients. We assessed the risk of 55 non-diabetic pediatric transplant recipients developing PTDM by performing OGTT prior to transplantation. For post-transplant immunosuppression, each patient received either a CsA- or a TAC-based regimen. However, recipients who had abnormal glucose tolerance in the pretransplant OGTT were allocated to the CsA-based regimen. The mean age of the patients was 9.7 +/- 5.4 yr while mean BMI was 16.5 +/- 3.3 kg/m2. FPG level before transplantation was within the normal limit in all patients, while the mean HbA1C value was 4.5. However, 18 of the 55 patients (32.7%) had abnormal glucose tolerance in the pretransplant OGTT, 13 (23.6%) had impaired glucose tolerance, and 5 (9.4%) had DM. PTDM developed in two patients on the TAC-based regimen with these patients having normal glucose tolerance prior to the transplant. In contrast, the 18 patients with abnormal glucose tolerance did not develop PTDM under CsA-based immunosuppression. Our results demonstrated an unexpectedly high prevalence of abnormal glucose tolerance in pretransplant OGTT even in a pediatric population. We believe that modification of post-transplant immunosuppression by the identification of high-risk patients using the pretransplant OGTT may minimize the development of new onset of PTDM.
authors.affiliation: Department of Pediatric Urology and Kidney Transplantation, Tokyo Metropolitan Kiyose Children's Hospital, Kiyose-shi, Tokyo, Japan. shishido@chp-kiyose-tokyo.jp
authors.forename: Seiichirou
authors.initials: S
authors.lastname: Shishido
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Sato
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Asanuma
authors.forename: Masahito
authors.initials: M
authors.lastname: Shindo
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hataya
authors.forename: Kenji
authors.initials: K
authors.lastname: Ishikura
authors.forename: Yuko
authors.initials: Y
authors.lastname: Hamasaki
authors.forename: Miwa
authors.initials: M
authors.lastname: Goto
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ikeda
authors.forename: Masataka
authors.initials: M
authors.lastname: Honda
mesh_terms: D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D003920:Diabetes Mellitus / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D018149:Glucose Intolerance / Q000097:blood / Q000150:complications / Q000453:epidemiology*; D019382:Human Growth Hormone / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000097:blood; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation; D008297:Male; D015995:Prevalence; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D001786:Blood Glucose; D007328:Insulin; D019382:Human Growth Hormone